BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating leukemic cells and the BCR-ABL1 transcripts per cell. BCR-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagani, Ilaria S., Dang, Phuong, Kommers, Ivar O., Goyne, Jarrad M., Nicola, Mario, Saunders, Verity A., Braley, Jodi, White, Deborah L., Yeung, David T., Branford, Susan, Hughes, Timothy P., Ross, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269287/
https://www.ncbi.nlm.nih.gov/pubmed/29976745
http://dx.doi.org/10.3324/haematol.2018.189787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269287/
https://www.ncbi.nlm.nih.gov/pubmed/29976745
http://dx.doi.org/10.3324/haematol.2018.189787

Ejemplares similares